Skip to main content
SpringerLink
Log in

Human lymphokine-activated killer (LAK) cells

I. Depletion of monocytes from peripheral blood mononuclear cells by L-Phenylalanine methyl ester: An optimization of LAK cell generation at high cell density

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Pretreatment of peripheral blood mononuclear cells (PBMC) with 5 mMl-phenylalanine methyl ester (PheOMe) provides an efficient means to deplete monocytes. PheOMe does not affect the number of large granular lymphocytes after the pretreatment, but does inhibit natural killer cell cytotoxicity temporarily after the pretreatment. However, depletion of monocytes by PheOMe allows lymphokine-activated killer (LAK) cell generation with recombinant interleukin-2 (rIL-2) at high cell density (> 5 × 106 cells/ml). The time of the PheOMe pretreatment is 40–60 min, though some effect could be observed within 15 min, and the pretreatment could be performed at room temperature. Pretreatment density of PBMC with 5 mM PheOMe could be achieved at cell density up to 3 × 107 cells/ml. PheOMe-pretreated cells could be activated by rIL-2 in serumless media at high cell density. Pretreatment of PBMC with 5 mM PheOMe provides an efficient means to deplete monocytes, as compared to plastic and nylonwool adherence. LAK cell generation is similar in both methods of monocyte depletion; therefore, depletion of monocytes allows, LAK cell generation at high cell density. The PheOMe procedure provides an improved and convenient process for preparing LAK cells for adoptive immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barlozzari T, Reynolds CW, Herberman RB (1983) In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol 131: 1024

    Google Scholar 

  2. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823

    Google Scholar 

  3. Helwig I, Groppe A (1972) Staining o constitutive heterochromatin in mammalian chromosomes with a new flurochrome. Exp Cell Res 75: 122

    Google Scholar 

  4. Hoyer M, Meineke T, Lewis W, Zwilling B, Rinehart J (1986) Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction. Cancer Res 46: 2834

    Google Scholar 

  5. Ibayashi Y, Hoon DSB, Golub SH (1987) The regulatory effect of adherent cells on lymphokine activated killer cells. Cell Immunol 110: 365

    Google Scholar 

  6. Kasid A, Bell GI, Director EP (1988) Effects of transforming growth factor-β on human lymphokine-activated killer cell precursors: autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 141: 690

    Google Scholar 

  7. Leung KH (1987) Improved process for preparing LAK cells byl-phenylalanine methyl ester pretreatment of peripheral blood mononuclear cells. Lymphokine Res 6, abstr 1817

    Google Scholar 

  8. Leung KH, Fischer DG, Koren HS (1983) Erythromyeloid tumor cells (K562) induce PGE synthesis in human peripheral blood monocytes. J Immunol 131: 445–449

    Google Scholar 

  9. Leung KH, Koren HS (1982) Regulation of human natural killing: II. Protective effect of interferon on NK cells from suppression by PGE2. J Immunol 129: 1742

    Google Scholar 

  10. Leung KH, Mihich E (1980) Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 288: 597

    Google Scholar 

  11. Mule JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA (1986) Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res 46: 676

    Google Scholar 

  12. Nii A, Sone S, Utsugi T, Yangawa H, Ogura T (1988) Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state. Int J Cancer 41: 33

    Google Scholar 

  13. Phillips JH, Lanier LL (1986) Dissection of the lymphokineactivated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164: 814

    Google Scholar 

  14. Rosenberg SA, Lotze MT, Mul JJ (1988) New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 108: 853

    Google Scholar 

  15. Silvennoinen O, Vakkila J, Hurme M (1988) Accessory cells, dendritic cells, or monocytes, are required for the lymphokine-activated killer cell induction from resting T cell but not from natural killer cell precursors. J Immunol 141: 1404

    Google Scholar 

  16. Thiele DL, Lipsky PE (1985) Regulation of cellular function by products of lysosomal enzyme activity: elimination of human natural killer cells by a dipeptide ethyl ester generated froml-leucine methyl ester by monocytes or polymorphonuclear leukocytes. Proc Natl Acad Sci USA 82: 2468

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Products Department, Business Planning & Development Division, Glenolden Laboratory, E. I. du Pont de Nemours and Co., 500 S. Ridgeway Avenue, 19036, Glenolden, PA, USA

    Kam H. Leung

Authors
  1. Kam H. Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leung, K.H. Human lymphokine-activated killer (LAK) cells. Cancer Immunol Immunother 30, 247–253 (1989). https://doi.org/10.1007/BF01665012

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01665012

Keywords

Search

Navigation